Schedule 13D ownership disclosure

REPARE THERAPEUTICS INC

Common Shares · CUSIP: 760273102

Event date: 2025-01-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • MPM BioVentures 2014, L.P.Reported CIK 0001609492

    Shares: 1,127,549.00 · Class: 2.7%

  • MPM BioVentures 2014 (B), L.P.Reported CIK 0001609493

    Shares: 75,206.00 · Class: 0.2%

  • MPM Asset Management Investors BV2014 LLCReported CIK 0001609495

    Shares: 38,809.00 · Class: 0.1%

  • UBS Oncology Impact Fund L.P.Reported CIK 0001691428

    Shares: 907,851.00 · Class: 2.1%

  • MPM BioVentures 2014 GP LLCReported CIK 0001765091

    Shares: 1,202,755.00 · Class: 2.8%

  • MPM BioVentures 2014 LLCReported CIK 0001765021

    Shares: 1,241,564.00 · Class: 2.9%

  • Oncology Impact Fund (Cayman) Management L.P.Reported CIK 0001721036

    Shares: 907,851.00 · Class: 2.1%

  • MPM BioImpact LLCReported CIK 0001687078

    Shares: 907,851.00 · Class: 2.1%

  • ANSBERT GADICKEReported CIK 0001134655

    Shares: 2,149,415.00 · Class: 5.1%

  • LUKE EVNINReported CIK 0001134657

    Shares: 1,241,564.00 · Class: 2.9%

  • Todd FoleyReported CIK 0001473930

    Shares: 1,241,564.00 · Class: 2.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-001509
Form type
SCHEDULE 13D/A
Filer
MPM BioVentures 2014, L.P.
CIK
CIK 1609492
Filed
Jan 15, 2025
Reporting period
Jan 13, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub